ArQule Inc. has announced it is expanding its oncology research, development and license agreement with Japanese pharmaceutical company Daiichi Sankyo. The deal expands the number of therapeutic targets under development and extends the deal for two years. The collaboration is based on the Cambridge biotech’s proprietary ArQule Kinase Inhibitor Platform (AKIP™) technology.
“This technology has provided us with a unique and innovative approach for discovery in the treatment of cancer,” said Dr. Hideyuki Haruyama, the Global Head of Research for Daiichi Sankyo, in a statement. “We expect that the expansion of this collaboration will produce other drug candidates and lay the foundation for future growth in this field.”